Detalles de la búsqueda
1.
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
Clin Exp Rheumatol
; 36(1): 50-55, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-28516874
2.
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
Rheumatology (Oxford)
; 56(11): 1993-2003, 2017 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28968735
3.
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
Lancet Rheumatol
; 5(2): e67-e76, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36923454
4.
Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
J Neurol
; 269(6): 3226-3237, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35066607
5.
Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers.
Vaccines (Basel)
; 9(10)2021 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34696287
6.
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.
RMD Open
; 7(2)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34330846
7.
Clinicopathological differences and correlations between right and left colon cancer.
World J Clin Cases
; 8(8): 1424-1443, 2020 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32368535
8.
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.
ACR Open Rheumatol
; 2(1): 18-25, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943974
Resultados
1 -
8
de 8
1
Próxima >
>>